Karyopharm therapeutics q2 loss per share $0.63

Karyopharm reports second quarter 2020 financial results and highlights recent company progress.q2 loss per share $0.63.q2 earnings per share estimate $-0.58 -- refinitiv ibes data.qtrly revenue $33.5 million versus $9.5 million.q2 revenue view $27.4 million -- refinitiv ibes data.karyopharm therapeutics - existing cash, cash equivalents & investments, xpovio sales, will be sufficient to fund planned operations in middle of 2022.
KPTI Ratings Summary
KPTI Quant Ranking